What is HanAll Pharmaceutical's contact information?

HanAll Pharmaceutical's contact information: 1644-5515, +13017383980.

How many employees does HanAll Pharmaceutical have?

HanAll Pharmaceutical has one employee.

What industry does HanAll Pharmaceutical belong to?

HanAll Pharmaceutical is in the industry of: Pharmaceuticals, Biotechnology, Health, Wellness And Fitness.

What are HanAll Pharmaceutical's official social media profiles?

HanAll Pharmaceutical Linkedin Page HanAll Pharmaceutical Twitter Page

What tech stack does HanAll Pharmaceutical use?

Some of the popular technologies that HanAll Pharmaceutical uses are: Cloudflare, Google Hosted Libraries, CDNJS, jQuery CDN, jsDelivr, Google Font API, GSAP.

What are HanAll Pharmaceutical's office addresses?

HanAll Pharmaceutical has 3 known office addresses: 서울시 강남구 봉은사로 114길 12 대웅제약빌딩 3층 Seoul, Seoul, KR Daewoong Building 3f, 12 Bongeunsa-ro 114-gil, Gangnam-gu, Seoul Teugbyeolsi, Kr, 06000.

What is HanAll Pharmaceutical's open headcount?

HanAll Pharmaceutical has no job postings yet.

What is the number of ad campaigns for HanAll Pharmaceutical?

HanAll Pharmaceutical has no advertisements yet.

What is the number of recent news articles about HanAll Pharmaceutical?

HanAll Pharmaceutical has 11 news articles.

HanAll Pharmaceutical - Pubrio Company Profile & Intent

HanAll Pharmaceutical

South Korea · Pharmaceuticals

Pharmaceuticals

Biotechnology

Health, Wellness And Fitness

한올바이오파마 is a global leader in pharmaceutical innovation, dedicated to developing new drugs that advance global health. The company focuses on creating innovative medications to meet the unmet needs of patients with difficult-to-treat diseases. Its R&D efforts span a range of therapeutic areas, including autoimmune diseases, dry eye treatment, immune-oncology, and metabolic cancer drugs.

Company Insights

smedaily.co.kr · is_developing · 4 weeks ago

Open news

HanAll Biopharma: Imvt-1402 clinical trials progressing well

HanAll Biopharma's autoimmune disease treatment Imvt-1402 is progressing well in clinical trials. Top-line results for refractory rheumatoid arthritis expected in second half of 2026.

Hanall Pharmaceutical

smedaily.co.kr · launches · 2025-11-14

Open news

KOSPI plunges 3.8% despite fact sheet release

KOSPI fell 3.81% despite US-Korea joint fact sheet release. Semiconductor and auto stocks dropped, while pharmaceutical and shipbuilding stocks rose. The decline was influenced by US stock market plunge and currency pressure.

docdocdoc.co.kr · launches · 2025-11-05

Open news

Welt launches DTx expansion strategy via telemedicine

Welt aims to achieve 10,000 SleepQ prescriptions by July next year, leveraging telemedicine platforms to expand digital therapeutics (DTx) market. CEO Kang Sung-ji emphasizes the need for industry collaboration and standardization.

Hanall Pharmaceutical

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin option investors bet on downside despite price rise

Bitcoin ETF and crypto-holding firms are buying put options to hedge against potential price drops below $60,000, despite recent price increases.

Coindesk

Deribit

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin's 'Death Cross' Appears: Future Trends?

Bitcoin chart shows 'death cross' pattern, historically preceding major price drops. Despite this, ETFs see $1 billion inflow and long-term investors continue accumulating.

Coindesk

Upbit Singapore

coinreaders.com · launches · one week ago

Open news

JPMorgan: Crypto Market Structure Act likely to pass mid-year

JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.

Coindesk

J.P. Morgan

Get full access to view complete information

1 - 11 of 11

Frequently Asked Questions Regarding HanAll Pharmaceutical

Company Overview

1973

Founded

Pharmaceuticals

Industry

South Korea

Location

13,280,429

Ranking

one employee

Size

Similar Companies

Get full access to view complete information